190 related articles for article (PubMed ID: 2537145)
21. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.
Markovits J; Linassier C; Fossé P; Couprie J; Pierre J; Jacquemin-Sablon A; Saucier JM; Le Pecq JB; Larsen AK
Cancer Res; 1989 Sep; 49(18):5111-7. PubMed ID: 2548712
[TBL] [Abstract][Full Text] [Related]
22. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
23. Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells.
Pommier Y; Kerrigan D; Covey JM; Kao-Shan CS; Whang-Peng J
Cancer Res; 1988 Feb; 48(3):512-6. PubMed ID: 2825977
[TBL] [Abstract][Full Text] [Related]
24. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
[TBL] [Abstract][Full Text] [Related]
26. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.
Potmesil M; Hsiang YH; Liu LF; Bank B; Grossberg H; Kirschenbaum S; Forlenza TJ; Penziner A; Kanganis D
Cancer Res; 1988 Jun; 48(12):3537-43. PubMed ID: 2836060
[TBL] [Abstract][Full Text] [Related]
27. Reduced DNA break formation and cytotoxicity of the topoisomerase II drug 4'-(9'-acridinylamino)methanesulfon-m-anisidide when combined with hyperthermia in human and rodent cell lines.
Kampinga HH; van den Kruk G; Konings AW
Cancer Res; 1989 Apr; 49(7):1712-7. PubMed ID: 2538233
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Pommier Y; Orr A; Kohn KW; Riou JF
Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
[TBL] [Abstract][Full Text] [Related]
29. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II.
Alexander RB; Nelson WG; Coffey DS
Cancer Res; 1987 May; 47(9):2403-6. PubMed ID: 2436763
[TBL] [Abstract][Full Text] [Related]
30. Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase.
Glisson BS; Sullivan DM; Gupta R; Ross WE
NCI Monogr; 1987; (4):89-93. PubMed ID: 2819738
[TBL] [Abstract][Full Text] [Related]
31. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Wolverton JS; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
[TBL] [Abstract][Full Text] [Related]
32. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
33. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
Barret JM; Calsou P; Larsen AK; Salles B
Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
[TBL] [Abstract][Full Text] [Related]
34. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA
Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964
[TBL] [Abstract][Full Text] [Related]
35. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
Leontiou C; Lakey JH; Austin CA
Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234
[TBL] [Abstract][Full Text] [Related]
36. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
Wolverton JS; Danks MK; Granzen B; Beck WT
Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
[TBL] [Abstract][Full Text] [Related]
37. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
38. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm C; Covey JM; Kerrigan D; Pommier Y
Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
[TBL] [Abstract][Full Text] [Related]
39. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
40. Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment.
Lawrence TS; Canman CE; Maybaum J; Davis MA
Cancer Res; 1989 Sep; 49(17):4775-9. PubMed ID: 2547516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
